請輸入關鍵字
請輸入關鍵字
訂購
*國家
中國
美國
中國香港
中國澳門
中國台灣
阿爾巴尼亞
阿爾及利亞
阿根廷
阿拉伯聯合酋長國
阿魯巴
阿曼
阿塞拜疆
阿森鬆島
埃及
埃塞俄比亞
愛爾蘭
愛沙尼亞
安道爾
安哥拉
安圭拉
安提瓜和巴布達
奧地利
奧蘭群島
澳大利亞
巴巴多斯
巴布亞新幾內亞
巴哈馬
巴基斯坦
巴拉圭
巴勒斯坦領土
巴林
巴拿馬
巴西
白俄羅斯
百慕大
保加利亞
北馬裏亞納群島
貝寧
比利時
冰島
波多黎各
波蘭
波斯尼亞和黑塞哥維那
玻利維亞
伯利茲
博茨瓦納
不丹
布基納法索
布隆迪
朝鮮
赤道幾內亞
丹麥
德國
迪戈加西亞島
東帝汶
多哥
多米尼加共和國
多米尼克
俄羅斯
厄瓜多爾
厄立特裏亞
法國
法羅群島
法屬波利尼西亞
法屬圭亞那
法屬南部領地
梵蒂岡
菲律賓
斐濟
芬蘭
佛得角
福克蘭群島
岡比亞
剛果(布)
剛果(金)
哥倫比亞
哥斯達黎加
格恩西島
格林納達
格陵蘭
格魯吉亞
古巴
瓜德羅普
關島
圭亞那
哈薩克斯坦
海地
韓國
荷蘭
荷屬加勒比區
荷屬聖馬丁
黑山
洪都拉斯
基裏巴斯
吉布提
吉爾吉斯斯坦
幾內亞
幾內亞比紹
加拿大
加納
加納利群島
加蓬
柬埔寨
捷克
津巴布韋
喀麥隆
卡塔爾
開曼群島
科科斯(基林)群島
科摩羅
科索沃
科特迪瓦
科威特
克羅地亞
肯尼亞
庫克群島
庫拉索
拉脫維亞
萊索托
老撾
黎巴嫩
立陶宛
利比裏亞
利比亞
聯合國
列支敦士登
留尼汪
盧森堡
盧旺達
羅馬尼亞
馬達加斯加
馬恩島
馬爾代夫
馬耳他
馬拉維
馬來西亞
馬裏
馬其頓
馬紹爾群島
馬提尼克
馬約特
毛裏求斯
毛裏塔尼亞
美國本土外小島嶼
美屬薩摩亞
美屬維爾京群島
蒙古
蒙特塞拉特
孟加拉國
秘魯
密克羅尼西亞
緬甸
摩爾多瓦
摩洛哥
摩納哥
莫桑比克
墨西哥
納米比亞
南非
南極洲
南喬治亞和南桑威奇群島
南蘇丹
瑙魯
尼加拉瓜
尼泊爾
尼日爾
尼日利亞
紐埃
挪威
諾福克島
帕勞
皮特凱恩群島
葡萄牙
日本
瑞典
瑞士
薩爾瓦多
薩摩亞
塞爾維亞
塞拉利昂
塞內加爾
塞浦路斯
塞舌爾
沙特阿拉伯
聖巴泰勒米
聖誕島
聖多美和普林西比
聖赫勒拿
聖基茨和尼維斯
聖盧西亞
聖馬丁島
聖馬力諾
聖皮埃爾和密克隆群島
聖文森特和格林納丁斯
斯裏蘭卡
斯洛伐克
斯洛文尼亞
斯瓦爾巴和揚馬延
斯威士蘭
蘇丹
蘇裏南
所羅門群島
索馬裏
塔吉克斯坦
泰國
坦桑尼亞
湯加
特克斯和凱科斯群島
特裏斯坦-達庫尼亞群島
特立尼達和多巴哥
突尼斯
圖瓦盧
土耳其
土庫曼斯坦
托克勞
瓦利斯和富圖納
瓦努阿圖
危地馬拉
委內瑞拉
文萊
烏幹達
烏克蘭
烏拉圭
烏茲別克斯坦
希臘
西班牙
西撒哈拉
新加坡
新喀裏多尼亞
新西蘭
匈牙利
休達及梅利利亞
敘利亞
牙買加
亞美尼亞
也門
伊拉克
伊朗
以色列
意大利
印度
印度尼西亞
英國
英屬維爾京群島
英屬印度洋領地
約旦
越南
讚比亞
澤西島
乍得
直布羅陀
智利
中非共和國
*省份
*城市
*姓名
*電話
*單位
*職位
*郵箱
*請輸入驗證碼
*驗證碼
B-hPD-1/hPD-L1/hC5AR1 mice
Strain Name
C57BL/6-Pdcd1tm1(PDCD1)Bcgen Cd274tm1(CD274)Bcgen C5ar1tm1(C5AR1)Bcgen/Bcgen
Common Name  B-hPD-1/hPD-L1/hC5AR1  mice
Background C57BL/6 Catalog number  131216
Related Genes 

PDCD1: CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1; 

CD274: B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1, PDL1, hPD-L1; C5AR1: C5A, C5AR, C5R1, CD88

NCBI Gene ID
18566,60533,12273

Protein expression analysis



from clipboard


Strain specific PD-1, PD-L1, C5AR1 expression analysis in homozygous B-hPD-1/hPD-L1/hC5AR1 mice by flow cytometry. Splenocytes were collected from wild-type C57BL/6 mice (+/+) and homozygous B-hPD-1/hPD-L1/hC5AR1 mice (H/H) for PD-1 and PD-L1 expression analysis; Bone marrow was collected from wild-type C57BL/6 mice (+/+) and homozygous B-hPD-1/hPD-L1/hC5AR1 mice (H/H) for C5AR1 expression analysis. Analyses were performed by flow cytometry with species-specific anti-PD-1, anti-PD-L1 and anti-C5AR1 antibody. Mouse PD-1, PD-L1, C5AR1 were detectable in wild-type C57BL/6 mice. Human PD-1, PD-L1, C5AR1 were exclusively detectable in homozygous B-hPD-1/hPD-L1/hC5AR1 mice but not in wild-type mice.

Analysis of leukocytes cell subpopulation in spleen


from clipboard


Analysis of spleen leukocyte subpopulations by FACS. Splenocytes were isolated from female C57BL/6 and B-hPD-1/hPD-L1/hC5AR1 mice (n=3, 6-week-old). Flow cytometry analysis of the splenocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T cells, B cells, NK cells, dendritic cells, granulocytes, monocytes and macrophages in homozygous B-hPD-1/hPD-L1/hC5AR1 mice were similar to those in the C57BL/6 mice, demonstrating that PD-1, PD-L1 and C5AR1 humanized does not change the overall development, differentiation or distribution of these cell types in spleen. Values are expressed as mean ± SEM.


Analysis of T cell subpopulation in spleen


from clipboard


Analysis of spleen T cell subpopulations by FACS. Splenocytes were isolated from female C57BL/6 and B-hPD-1/hPD-L1/hC5AR1 mice (n=3, 6-week-old). Flow cytometry analysis of the splenocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live CD45+ cells were gated for TCRβ+ T cell population and used for further analysis as indicated here. B. Results of FACS analysis. The percent of CD4+ T cells, CD8+ T cells and Tregs in homozygous B-hPD-1/hPD-L1/hC5AR1 mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hPD-1, PD-L1 and C5AR1 in place of its mouse counterpart does not change the overall development, differentiation or distribution of these T cell subtypes in spleen. Values are expressed as mean ± SEM.

Analysis of leukocytes cell subpopulation in lymph node

from clipboard


Analysis of lymph node leukocyte subpopulations by FACS. Lymph nodes were isolated from female C57BL/6 and B-hPD-1/hPD-L1/hC5AR1 mice (n=3, 6-week-old). Flow cytometry analysis of the splenocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T cells, B cells, NK cells, dendritic cells, granulocytes, monocytes and macrophages in homozygous B-hPD-1/hPD-L1/hC5AR1 mice were similar to those in the C57BL/6 mice, demonstrating that PD-1, PD-L1 and C5AR1 humanized does not change the overall development, differentiation or distribution of these cell types in lymph node. Values are expressed as mean ± SEM.


Analysis of T cell subpopulation in lymph node


from clipboard


Analysis of lymph node T cell subpopulations by FACS. Leukocytes were isolated from female C57BL/6 and B-hPD-1/hPD-L1/hC5AR1 mice (n=3, 6-week-old). Flow cytometry analysis of the leukocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live CD45+ cells were gated for TCRβ+ T cell population and used for further analysis as indicated here. B. Results of FACS analysis. The percent of CD4+ T cells, CD8+ T cells, and Tregs in homozygous B-hPD-1/hPD-L1/hC5AR1 mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hPD-1, PD-L1 and C5AR1 in place of its mouse counterpart does not change the overall development, differentiation or distribution of these T cell subtypes in lymph node. Values are expressed as mean ± SEM.

Analysis of leukocytes cell subpopulation in blood

from clipboard


Analysis of blood leukocyte subpopulations by FACS. Blood cells were isolated from female C57BL/6 and B-hPD-1/hPD-L1/hC5AR1 mice (n=3, 6-week-old). Flow cytometry analysis of the blood cells was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T cells, B cells, NK cells, dendritic cells, granulocytes, monocytes and macrophages in homozygous B-hPD-1/hPD-L1/hC5AR1 mice were similar to those in the C57BL/6 mice, demonstrating that PD-1, PD-L1 and C5AR1 humanized does not change the overall development, differentiation or distribution of these cell types in blood. Values are expressed as mean ± SEM.

Analysis of T cell subpopulation in blood

from clipboard


Analysis of blood T cell subpopulations by FACS. Blood cells were isolated from female C57BL/6 and B-hPD-1/hPD-L1/hC5AR1 mice (n=3, 6-week-old). Flow cytometry analysis of the blood cells was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live CD45+ cells were gated for TCRβ+ T cell population and used for further analysis as indicated here. B. Results of FACS analysis. The percent of CD4+ T cells, CD8+ T cells, and Tregs in homozygous B-hPD-1/hPD-L1/hC5AR1 mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hPD-1, PD-L1 and C5AR1 in place of its mouse counterpart does not change the overall development, differentiation or distribution of these T cell subtypes in blood. Values are expressed as mean ± SEM.


Antibody binding assay


from clipboard


Antibody binding analysis of B-hPD-1/hPD-L1/hC5AR1 mice by FACS. Splenocytes were isolated from wild-type C57BL/6 mice (+/+) and homozygous B-hPD-1/hPD-L1/hC5AR1 mice (H/H). Anti-hC5AR1 antibody avdoralimab (in house) can bind CD11b+ cells in spleen of B-hPD-1/hPD-L1/hC5AR1 mice. But the antibody can not bind the cells in spleen of wild-type C57BL/6 mice. Thus the anti-hC5AR1 antibody can specifically bind cells of B-hPD-1/hPD-L1/hC5AR1 mice.




In vivo efficacy of combination of anti-human PD-1 antibody and anti-human C5AR1 antibody


from clipboard


Antitumor activity of combination of anti-human PD-1 antibody (pembrolizumab, in house) and anti-human C5AR1 antibodies (avdoralimab, in house) in B-hPD-1/hPD-L1/hC5AR1 mice. (A) combination of anti-human PD-1 antibody and anti-human C5AR1 antibody inhibited B-hPD-L1 MC38 plus tumor growth in B-hPD-1/hPD-L1/hC5AR1 mice. Murine colon cancer B-hPD-L1 MC38 plus cells were subcutaneously implanted into homozygous B-hPD-1/hPD-L1/hC5AR1 mice (female, 7-9-week-old, n=6). Mice were grouped when tumor volume reached approximately 100 mm3, at which time they were treated with anti-human PD-1 antibody and anti-human C5AR1 antibody with doses and schedules indicated in panel. (B) Body weight changes during treatment. As shown in panel A, combination of anti-human PD-1 antibody and anti-human C5AR1 antibody were efficacious in controlling tumor growth in B-hPD-1/hPD-L1/hC5AR1 mice, demonstrating that the B-hPD-1/hPD-L1/hC5AR1 mice provide a powerful preclinical model for in vivo evaluation of combination of anti-human PD-1 antibody and anti-human C5AR1 antibody. Values are expressed as mean ± SEM.


In vivo efficacy of combination of anti-human PD-1 antibody and anti-human C5AR1 antibody

from clipboard

Antitumor activity of combination of anti-human PD-1 antibody (pembrolizumab, in house) and anti-human C5AR1 antibodies (avdoralimab, in house) in B-hPD-1/hPD-L1/hC5AR1 mice. (A) combination of anti-human PD-1 antibody and anti-human C5AR1 antibody inhibited B-hPD-L1 MC38 plus tumor growth in B-hPD-1/hPD-L1/hC5AR1 mice. Murine colon cancer B-hPD-L1 MC38 plus cells were subcutaneously implanted into homozygous B-hPD-1/hPD-L1/hC5AR1 mice (female, 5-8-week-old, n=6). Mice were grouped when tumor volume reached approximately 100 mm3, at which time they were treated with anti-human PD-1 antibody and anti-human C5AR1 antibody with doses and schedules indicated in panel. (B) Body weight changes during treatment. As shown in panel A, combination of anti-human PD-1 antibody and anti-human C5AR1 antibody were efficacious in controlling tumor growth in B-hPD-1/hPD-L1/hC5AR1 mice, demonstrating that the B-hPD-1/hPD-L1/hC5AR1 mice provide a powerful preclinical model for in vivo evaluation of combination of anti-human PD-1 antibody and anti-human C5AR1 antibody. Values are expressed as mean ± SEM.